Related Experiment Video
Updated: Mar 21, 2026
10:03
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
Published on: February 28, 2013
26.7K
Extracellular microRNAs and endothelial hyperglycaemic memory: a therapeutic opportunity?
F Prattichizzo1,2, A Giuliani2, V De Nigris1
1Insititut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Barcelona, Spain.
Diabetes, Obesity & Metabolism
|May 11, 2016
Summary
MicroRNAs (miRNAs) are implicated in type 2 diabetes mellitus (T2DM)-related cardiovascular disease by affecting endothelial function, inflammaging, and cellular senescence. Extracellular vesicles carrying miRNAs may offer a therapeutic strategy to mitigate T2DM
Area of Science:
- Endocrinology
- Molecular Biology
- Cardiovascular Science
Background:
- Type 2 diabetes mellitus (T2DM) significantly increases cardiovascular disease (CVD) risk.
- Standard interventions partially mitigate CVD risk, suggesting complex underlying mechanisms.
- Endothelial dysfunction, inflammaging, and cellular senescence contribute to T2DM-related CVD.
Purpose of the Study:
- To review the role of microRNAs (miRNAs) in T2DM-associated endothelial dysfunction, inflammaging, and cellular senescence.
- To explore the potential of miRNA-based therapies, particularly using extracellular vesicles, for T2DM complications.
Main Methods:
- Literature review of recent evidence on miRNA deregulation in T2DM.
- Focus on miRNAs modulating endothelial function, inflammaging, and cellular senescence.
- Discussion of miRNA-containing extracellular vesicles as a therapeutic approach.
Main Results:
- MiRNA deregulation is associated with T2DM progression and age-related diseases.
- Specific diabetes-associated miRNAs influence endothelial function, inflammaging, and senescence.
- Extracellular vesicles can transport functional miRNAs between cells and tissues.
Conclusions:
- MiRNAs play a critical role in the pathogenesis of T2DM complications.
- Targeting miRNA pathways, potentially via extracellular vesicles, offers a novel therapeutic avenue.
- Restoring physiological miRNA signatures could prevent or delay T2DM-related systemic damage.
